BioCryst Pharmaceuticals, Inc.

NASDAQ:BCRX

Biotechnology

Healthcare
$7.32 +1.02%

+$0.09 today

Market cap
$1.88B
Beta
0.56
P/E (TTM)
-4.8
EPS (TTM)
-$1.89
52W Low $6.00High $10.32

Volume 3.78M

Average 4.85M

Returns on capital

BioCryst Pharmaceuticals, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-221.4%

avg 73.6%

ROIC

105.2%

avg -35.3%

ROA

51.3%

avg -36.9%

Analysis

ROIC is currently the strongest return metric at 105.2% versus its period average of -35.3%. 2 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Charles K. Gayer

CEO, President & DirectorUSD 1.38M550<0.01%

Alane Barnes

Senior Vice President, Chief Legal Officer & Corporate SecretaryUSD 1.11M60——

Babar Ghias

Chief Financial Officer & Head of Corporate DevelopmentUSD 948.42K47268.70K0.13%

William Sheridan MBBS

Chief Development OfficerUSD 784.09K71——

Yarlagadda S. Babu

Chief Discovery OfficerUSD 691.45K730<0.01%

John Ruesch

Chief Technical Operations Officer————

Jinky Ang Rosselli

Chief Data Innovation Officer————

Stephanie Angelini

Chief People Officer & Communications Officer————

Nick Wilder

Manager of Investor Relations————

David W. Jenkins

Chief Scientific Officer————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Dec 22, 2025.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

0

$0.00

Sells

9

$4.07M

Net Transaction Value

−$4.07M

Net selling

Most Active

Barnes Alane P

7 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
May 18, 26

McKee Amy E

Direct

Sell$100.3K
May 13, 26

Barnes Alane P

Direct

Sell$596.3K
Mar 20, 26

HEGGIE THERESA

Direct

Sell$504.8K
Mar 16, 26

Barnes Alane P

Direct

Sell$1.4M
Dec 22, 25

Barnes Alane P

Direct

Sell$166.6K
Dec 15, 25

Barnes Alane P

Direct

Sell$162.3K
Dec 3, 25

Barnes Alane P

Direct

Sell$151.2K
Dec 2, 25

Barnes Alane P

Direct

Sell$367.2K
Dec 1, 25

Barnes Alane P

Direct

Sell$646.5K

Summary

Insiders reported 0 buys worth $0.00 and 9 sells worth $4.07M over the last 12 months. That adds up to net selling of $4.07M. Barnes Alane P was the most active insider with 7 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
-1.7% (5yr)4 analysts
RevenueN/AN/A+47.8%
+4.7% (5yr)6 analysts
Net IncomeN/AN/AN/A
-1.6% (5yr)6 analysts
EBITN/AN/AN/A
+3.4% (5yr)6 analysts

Analysis

Recent growth has been strongest in Revenue at +47.8% over three years. Forward estimates point to Revenue at +4.7% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does BioCryst Pharmaceuticals, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about BCRX's management, answered from reported figures.

Who manages BCRX?

BioCryst Pharmaceuticals, Inc. (BCRX) lists 10 active executives. The top listed executive is Yarlagadda S. Babu, Chief Discovery Officer.

Are BCRX insiders buying or selling?

Recent insider activity shows net buying of $37.20M.